Sign inJoin waitlistJoin the waitlist

Hanny Al-Samkari

Physician · Massachusetts General Hospital

Credentials: · · · · ·

History

Massachusetts General Hospital
Present

Hematology and Medical Oncology
Dana-Farber Cancer Institute
2015–2018
Hematology and Medical Oncology
Massachusetts General Hospital
2015–2018
Hospital of the University of Pennsylvania
2011–2014
Washington University School of Medicine
2007–2011

Research

COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection
Blood · 2020 · First of 13 authors · Corresponding · 951 citations
Second International Guidelines for the Diagnosis and Management of Hereditary Hemorrhagic Telangiectasia
Annals of Internal Medicine · 2020 · 425 citations
Hemophagocytic Lymphohistiocytosis
Review · Annual review of pathology · 2018 · First of 2 authors · Corresponding · 407 citations

DK
David Kuter
31 papers
Rachael Grace
18 papers
AS
Andrew Song
14 papers · 13 as a resident
Jean Connors
14 papers
Vivek Iyer
12 papers
Raj Kasthuri
11 papers
DL
David Leaf
10 papers
Josanna Rodriguez-Lopez
10 papers
KG
Katayoon Goodarzi
10 papers
Allyson Pishko
9 papers
Ketih McCrae
9 papers
SS
Sujit Sheth
9 papers

Grants

Antiangiogenic Therapy to Reduce Bleeding and Improve Health-Related Quality of Life in Hereditary Hemorrhagic Telangiectasia
National Heart, Lung, and Blood Institute · K23
Contact PI · $999K · Massachusetts General Hospital
2022–2027

Clinical trials

Avatrombopag vs. Placebo for CIT in GI Malignancies
Principal investigator · Completed · Phase 2
Hanny Al-Samkari, MD
2023–2026
Acquired Pyruvate Kinase Deficiency In Clonal Myeloid Neoplasms
Principal investigator · Completed
Massachusetts General Hospital
2022–2026
Bevacizumab In Hereditary Hemorrhagic Telangiectasia
Principal investigator · Active not recruiting · Phase 2
Hanny Al-Samkari, MD
2020–2027
The BENeFiTS Trial in Beta Thalassemia Intermedia
Principal investigator · Enrolling by invitation · Phase 1, Phase 2
Phoenicia BioScience
2020–2026